Could pets be next for weight loss drugs? Here’s what to know about a clinical study for cats.

2 1 minute read

GLP-1 Weight Loss Drugs for Pets: A New Frontier in Pet Healthcare

Okava Pharmaceuticals, a San Francisco-based company, has recently introduced MEOW-1, a groundbreaking clinical study aimed at bringing GLP-1 weight loss drugs to pets. The study involves the use of a tiny, under-the-skin implant called OKV-119 in 50 cats to release a GLP-1 medication over a period of six months.

According to Michael Klotsman, the CEO of Okava Pharmaceuticals, the OKV-119 implant is designed to replicate the physiological effects of fasting, such as improved insulin sensitivity, reduced fat mass, and more efficient energy metabolism. This innovative approach aims to enhance cats’ quality of life and promote healthy aging without requiring significant changes in feeding routines.

Dr. Ernie Ward, a renowned pet obesity expert, emphasized the limitations of traditional approaches to pet weight management, stating, “For the last 100 years, the only prescription we had was feed less, exercise more, and that just doesn’t work for all types of obesity.” He highlighted the potential benefits of GLP-1 drugs for pets, citing human data that shows improvements in diabetes risk and overall health.

The MEOW-1 trial will provide crucial insights into the efficacy, side effects, and cost of the GLP-1 weight loss therapy for pets. Okava Pharmaceuticals aims to make the drug affordable for pet owners, with a target cost of approximately $100 per month.

Savannah Tielking, a pet owner, expressed her willingness to consider the GLP-1 therapy for her 10-year-old cat Runkle, who struggles with obesity. She shared, “If my vet recommended it for his diabetes and other health issues, I would definitely consider it.”

The results of the MEOW-1 trial are expected to be released next summer, paving the way for FDA approval of GLP-1 drugs for cats within the next two years. Additionally, Okava Pharmaceuticals plans to extend the use of these innovative drugs to dogs in the near future.